Article

Ketotifen drop designed to provide ocular itching relief

A new ketotifen fumarate ophthalmic solution (Refresh Eye Itch Relief, Allergan) offers patients another option for the treatment of episodic ocular itching as well as seasonal and chronic allergic conjunctivitis.

Key Points

The new drop is available over the counter but has the same efficacy as the original prescription formula of ketotifen, according to the company. It has a triple-action formulation designed to offer an antihistamine effect in minutes for relief from ocular allergies, mast cell stabilization to sustain relief for up to 12 hours, and eosinophil inhibition to prevent late-phase allergic reaction. It is safe for adults as well as children aged 3 or more years, according to the company.

Dr. Luchs, also director of the refractive surgical service at North Shore-Long Island Jewish Health System, Great Neck, NY, and in private practice with South Shore Eye Care, Wantagh and Massapequa, NY, told Ophthalmology Times that he has made patients aware of the availability of this treatment option on the market. The solution's active ingredient, ketotifen, is part of the most-prescribed class of drugs (antihistamine/mast cell stabilizers) that has been shown to work well against seasonal and chronic allergic conjunctivitis, he said.

"Ketotifen is an excellent mast cell stabilizer and has some anti-inflammatory properties against some of the other cells and mediators involved further down the cascade," he continued.

Patient feedback

His patients appreciate that the drop is accessible without a prescription, Dr. Luchs told Ophthalmology Times, adding that cost has not been an issue for his patients, either. "The feedback I've gotten from patients who have used it has been generally positive. It's certainly efficacious," he said.

"Ketotifen has always been an excellent antihistamine/mast cell stabilizer. It makes a nice addition to the drugs that we have available to treat allergic conjunctivitis. All the drugs in this class . . . work very well for treating ocular allergies, and ketotifen has always been very well tolerated and very effective in my patient population," Dr. Luchs concluded.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.